Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study
Open Access
- 11 August 2023
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (9) , 1359-1369
Abstract
Objective To evaluate clinicopathologic features and oncologic outcomes of patients with neuroendocrine cervical carcinoma in an institutional neuroendocrine cervical tumor registry. Methods Retrospective study including patients with neuroendocrine cervical carcinomas diagnosed between 1986 and 2022. Patients were categorized into International Federation of Gynecology and Obstetrics 2018 stage groups: early-stage (IA1–IB2, IIA1); locally advanced (IB3, IIA2–IVA); and advanced (IVB). Clinicopathologic characteristics and oncologic outcomes were evaluated by stage. Survival was compared between patients diagnosed in 1986–2003 and those diagnosed in 2004–2016. Progression-free and overall survival were estimated using the Kaplan-Meier product-limit estimator. Results A total of 453 patients was included, 133 (29%) with early-stage, 226 (50%) with locally advanced, and 94 (21%) with advanced disease. Median age was 38 years (range 21–93). Sixty-nine percent (306/453) had pure and 32% (146/453) had mixed histology. The node positivity rate (surgical or radiological detection) was 19% (21/108) for tumors ≤2 cm, 37% (39/105) for tumors >2 to ≤4 cm, and 61% (138/226) for tumors >4 cm (pConclusion Among patients with neuroendocrine cervical carcinomas, overall survival is favorable for patients with early-stage disease. However, most patients present with locally advanced disease, and overall survival remains poor in this subgroup. For patients with advanced disease, receiving cisplatin/carboplatin plus etoposide and curative radiation therapy is associated with improved overall survival.Keywords
Funding Information
- Small/Large Cell Carcinoma of the Cervix: Sisters United
- National Cancer Institute (P30CA016672)
This publication has 15 references indexed in Scilit:
- Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR studyInternational Journal of Gynecological Cancer, 2021
- Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategyGynecologic Oncology, 2019
- Updates and management algorithm for neuroendocrine tumors of the uterine cervixInternational Journal of Gynecological Cancer, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Revised FIGO staging for carcinoma of the cervix uteriInternational Journal of Gynecology & Obstetrics, 2019
- Prognostic factors and optimal therapy for stages I–II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective studyGynecologic Oncology, 2018
- Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervixGynecologic Oncology, 2017
- Primary surgery versus primary radiation therapy for FIGO stages I–II small cell carcinoma of the uterine cervix: A retrospective Taiwanese Gynecologic Oncology Group studyGynecologic Oncology, 2015
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Small-Cell Carcinoma of the Cervix: Fourteen Years of Experience at a Single Institution Using a Combined-Modality Regimen of Involved-Field Irradiation and Platinum-Based Combination ChemotherapyJournal of Clinical Oncology, 2003